{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=82",
    "query": {
      "intervention": "Placebo Intravenous",
      "page": 82
    },
    "page_size": 10
  },
  "pagination": {
    "page": 82,
    "page_size": 10,
    "total_count": 2348,
    "total_pages": 235,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=83&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=81&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T04:26:37.967Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01785056",
      "title": "IVIG Treatment in Systemic Sclerosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Diffuse Scleroderma"
      ],
      "interventions": [
        {
          "name": "Privigen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2013-04",
      "completion_date": "2019-01",
      "has_results": false,
      "last_update_posted_date": "2018-07-17",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01785056"
    },
    {
      "nct_id": "NCT03125902",
      "title": "A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab Placebo",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 653,
      "start_date": "2017-08-25",
      "completion_date": "2023-01-17",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 8,
      "location_summary": "Stanford, California • Fort Myers, Florida • St. Petersburg, Florida + 5 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03125902"
    },
    {
      "nct_id": "NCT02013700",
      "title": "Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis (IPF)"
      ],
      "interventions": [
        {
          "name": "Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "matched placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Joshua M Hare",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 9,
      "start_date": "2013-11-13",
      "completion_date": "2016-11-24",
      "has_results": false,
      "last_update_posted_date": "2021-03-09",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013700"
    },
    {
      "nct_id": "NCT01808261",
      "title": "Proof of Concept (POC) in Patients With Ischaemic Stroke",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cerebrovascular Accident"
      ],
      "interventions": [
        {
          "name": "GSK249320 100/mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 134,
      "start_date": "2013-05-18",
      "completion_date": "2014-07-28",
      "has_results": true,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 6,
      "location_summary": "Orange, California • Jacksonville, Florida • Peoria, Illinois + 3 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01808261"
    },
    {
      "nct_id": "NCT04225923",
      "title": "A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Disease"
      ],
      "interventions": [
        {
          "name": "NPC-21 Low dose",
          "type": "DRUG"
        },
        {
          "name": "NPC-21 High dose",
          "type": "DRUG"
        },
        {
          "name": "NPC-21 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nobelpharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "18 Years to 76 Years"
      },
      "enrollment_count": 87,
      "start_date": "2020-06-01",
      "completion_date": "2023-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225923"
    },
    {
      "nct_id": "NCT04503603",
      "title": "A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Lanadelumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2020-08-10",
      "completion_date": "2020-12-23",
      "has_results": true,
      "last_update_posted_date": "2022-03-07",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04503603"
    },
    {
      "nct_id": "NCT00822341",
      "title": "Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "TG-0054",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GPCR Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 64,
      "start_date": "2008-04",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2021-08-04",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00822341"
    },
    {
      "nct_id": "NCT01932554",
      "title": "Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Hb-SS Disease With Vasoocclusive Pain",
        "Hemoglobin SS Disease With Vasoocclusive Crisis",
        "Other Sickle Cell Disease With Vaso-Occlusive Pain",
        "Hemoglobin SS Disease With Crisis"
      ],
      "interventions": [
        {
          "name": "Abciximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Intravenous hydration",
          "type": "OTHER"
        },
        {
          "name": "Ibuprofen",
          "type": "DRUG"
        },
        {
          "name": "Parenteral narcotic",
          "type": "DRUG"
        },
        {
          "name": "Incentive spirometry",
          "type": "OTHER"
        },
        {
          "name": "Supplemental oxygen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "5 Years to 25 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-11",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-03-26",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01932554"
    },
    {
      "nct_id": "NCT00186069",
      "title": "Magnesium Sulfate vs Placebo for Placental Abruption",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Abruptio Placentae"
      ],
      "interventions": [
        {
          "name": "Magnesium Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2004-03",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2018-01-02",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 2,
      "location_summary": "San Jose, California • Stanford, California",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00186069"
    },
    {
      "nct_id": "NCT00300196",
      "title": "ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke",
        "Cerebral Ischemia",
        "Brain Infarction"
      ],
      "interventions": [
        {
          "name": "Ancrod (Viprinex)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Neurobiological Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2006-03",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2010-01-12",
      "last_synced_at": "2026-10-23T04:26:37.967Z",
      "location_count": 39,
      "location_summary": "Chico, California • Fresno, California • La Mesa, California + 32 more",
      "locations": [
        {
          "city": "Chico",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00300196"
    }
  ]
}